Viruses, Immunity, and Cancer

  • C. W. Potter
  • R. C. Rees
Part of the Developments in Oncology book series (DION, volume 21)


Reading the scientific and medical literature is difficult without feeling swamped by suggested causes of human cancer: genetic factors have been implicated; epidemiological studies based on geographic variations in cancer incidence have suggested a variety of environmental factors [1]; multiple elements in our food and diet have been indicted at various times; and many fashions of western and eastern society have been held to contain factors that increase the incidence of malignant diseases [2]. With this in mind, it is not surprising that virus infection has been associated with the aetiology of cancer; however, this theory deserves attention, since it is supported by a large body of circumstantial evidence, and under strictly controlled conditions, viruses can be shown to induce many forms of cancer in a variety of animal species. These observations have led many authorities to suggest that viruses are aetiological agents of malignant disease in man, but the inability to carry out the experiments that proved the association of viruses and cancer in animals has meant that direct proof of association cannot be made for human cancers.


Cervical Cancer Herpes Simplex Virus Type Simian Virus Sezary Syndrome Transplantation Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cairns J. The cancer problem. Sci Amer 233: 64–72, 1975.PubMedCrossRefGoogle Scholar
  2. 2.
    Weisburgher JH, Williams GM. Metabolism of chemical carcinogens. In Becker FF (ed.), Cancer. Etiology; chemical and physical carcinogenesis. New York: Plenum Press, 1975.Google Scholar
  3. 3.
    Ellerman V, Bang O. Experimentelle leukaemie bei huhnern. Centr Bakteriol Abt 1: 559–601, 1908.Google Scholar
  4. 4.
    Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumour cells. J Exp Med 13: 397–411, 1911.PubMedCrossRefGoogle Scholar
  5. 5.
    Moses A. O virus do mixoma dos collhos. Mem Inst Oswald-Cruz. 3: 46–53, 1911.CrossRefGoogle Scholar
  6. 6.
    Shope RE. Filterable virus causing tumour-like condition in rabbits and its relationship to virus myxomatosum. J Exp Med 56: 803–822, 1932.PubMedCrossRefGoogle Scholar
  7. 7.
    Shope RE. Infectious papillomatosis of rabbits. J Exp Med 58: 607–625, 1933.PubMedCrossRefGoogle Scholar
  8. 8.
    Furth J. Lymphomatosis, myelomatosis and endothelioma of chickens caused by a filterable agent. J Exp Med 58: 253–275, 1933.PubMedCrossRefGoogle Scholar
  9. 9.
    Bittner JJ. Some possible effects of nursing on mammary gland tumour incidence in mice. Science 84: 162, 1936.PubMedCrossRefGoogle Scholar
  10. 10.
    Lucke B, Carcinoma of the leopard frog: Its probable causation by a virus. J Exp Med 68: 457–468, 1938.PubMedCrossRefGoogle Scholar
  11. 11.
    Sweet BH, Hilleman MR. The vacuolating virus SV40. Proc Soc Exp Biol Med 105: 420–427, 1960.PubMedGoogle Scholar
  12. 12.
    Rabson AS, O’Connor GT, Kirschstein RL, Branigan WJ. Papillary ependymomas produced in Rattus (Mastomys) Natalensis inoculated with vacuolating virus (SV40). J Natl Cancer Inst 29: 765–787, 1962.PubMedGoogle Scholar
  13. 13.
    Trenton JJ, Yabe Y, Taylor G. The quest for human cancer viruses. Science 137: 835–841, 1962.CrossRefGoogle Scholar
  14. 14.
    Huebner RJ. Adenovirus-directed tumour and T-antigens. In Pollard M (ed.), Perspectives in virology. 5: 147–166, 1967.Google Scholar
  15. 15.
    Jordan WS, Badger GF, Dingle JH. A study of type-specific adenovirus antibodies in the first five years of life—Implications for the use of adenovirus vaccine. N Eng J Med 258: 1041–1044, 1958.CrossRefGoogle Scholar
  16. 16.
    Tooze J. Structure and composition of polyoma, SV40 and the Papillomaviruses. In Watson J (ed.), Origins of human cancer. New York: Cold Spring Harbor, 1977.Google Scholar
  17. 17.
    Zur Hausen H. Human Papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78: 1–30, 1977.PubMedGoogle Scholar
  18. 18.
    Stewart SE, Eddy BE, Borgese N. Neoplasms in mice inoculated with a tumour agent carried in tissue culture. J Nat Cancer Inst 20: 1223–1236, 1958.PubMedGoogle Scholar
  19. 19.
    Carr I, McGinty FM, Potter CW. Neoplastic metastasis of transplantable animal neoplasms. Experimenta 3D: 185–186, 1974.CrossRefGoogle Scholar
  20. 20.
    Huebner RJ. Tumours induced by adenoviruses. In Pollard M (ed.), Perspectives in virology. New York: Academic Press, 1967.Google Scholar
  21. 21.
    Sarma PS, Heubner RJ, Lane WT. Induction of tumours in hamsters with an avian adenovirus (CELO). Science 149: 1108, 1965.PubMedCrossRefGoogle Scholar
  22. 22.
    Hull RN, Johnson IS, Cuthbertson CG, Reimer CB, Wright HF. Oncogenicity of the simian adenoviruses. Science 150: 1044–1046, 1965.PubMedCrossRefGoogle Scholar
  23. 23.
    Gilden RJ, Kern J, Beddow TG, Heubner RJ. Bovine adenovirus type 3: Detection of specific tumour and T-antigens. Virology 31: 727–729, 1967.PubMedCrossRefGoogle Scholar
  24. 24.
    Brandt CD, Kim HW, Varsosky AJ, Jeffries BC, Arrobio JO, Rindge B, Parrott RH, Chanock RM. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I Adenoviruses. Amer J Epidemiol 90: 484–500, 1969.Google Scholar
  25. 25.
    Potter CW, Sheddon WIH. The distribution of adenovirus antibodies in normal children. J Hyg (Camb.) 61: 155–160, 1963.CrossRefGoogle Scholar
  26. 26.
    Potter CW, Schild GC. Antibodies in human sera to adenoviruses (types 7, 12, and 18). Arch Ges Virus- forsch 18: 80–87, 1966.Google Scholar
  27. 27.
    Green M, Mackey JK. Are oncogenic human adenoviruses associated with human cancer? Cold Spring Har-bor Conf. Cell Proliferation 4: 1027–1031, 1977.Google Scholar
  28. 28.
    Rafferty KA. The cultivation of inclusion-associated viruses from Lucke tumours frogs. Ann NY Acad Sci 126: 3–21, 1965.PubMedCrossRefGoogle Scholar
  29. 29.
    Naegele RF, Granoff A, Darlington RW. The presence of the Lucke’ Herpesvirus genome in induced tadpole tumours and its oncogenicity. Proc Natl Acad Sci (USA) 71: 830–834, 1974.CrossRefGoogle Scholar
  30. 30.
    Purchase HG: Marek’s disease virus and the Herpesvirus of turkeys. Prog Med Virol 18: 178–197, 1974.PubMedGoogle Scholar
  31. 31.
    Payne LN, Biggs PM. Studies on Marek’s disease. II. Pathogenesis. J Natl Cancer Inst 39: 281–291, 1967.Google Scholar
  32. 32.
    Hunt RD, Melendez LV, Garcia G, Trum BF. Pathologic features of Herpesvirus ateles lymphoma in cotton- topped marmosets (Saguinas oedipus). J Natl Cancer Inst 49: 1631–1638, 1972.PubMedGoogle Scholar
  33. 33.
    Niven JSF, Armstrong JA, Andrewes CH, Pereira HG, Valentine RC. Subcutaneous growths in monkeys produced by a poxvirus. J Path Bact 81: 1–14, 1961.PubMedCrossRefGoogle Scholar
  34. 34.
    Blair FB. The mammary tumour virus (MTV). In Current topics in microbiology. New York: Springer Verlag 45: 1–69, 1968.Google Scholar
  35. 35.
    Hageman PC, Calafat J, Daams JH. The mouse mammary tumour viruses. In Emmelot P, Bentvelsen P (eds.), RNA viruses and the host genome in oncogenesis. Amsterdam: North Holland, 1972.Google Scholar
  36. 36.
    Panem S, Reynolds JT. Retrovirus expression in normal and pathogenic processes of man. Fed Proc 38: 2674–2678, 1979.PubMedGoogle Scholar
  37. 37.
    Essex M, Cotter SM, Hardy WD, Hess P, Jarrett W, Jarrett O, Mackey L, Laid H, Perryman L, Olsen RG, Young DS. Antibody titres in cats with naturally occurring leukaemia, lymphoma and other diseases. J Nat Cancer Inst 55: 463–467, 1975.PubMedGoogle Scholar
  38. 38.
    Theilen GH, Wolfe LG, Rabin H, Deinhardt F, Dungworth DL, Fowler ME, Gould D, Cooper R. Biological studies of four species of nonhuman primates with simian sarcoma virus. Bibl Haematol 39: 251–257, 1973.PubMedGoogle Scholar
  39. 39.
    McAllister RM, Nicolson MO, Reed G, Kern J, Gilden RV, Huebner RJ. Transformation of rodent cells by adenovirus 19 and other group D adenoviruses. J Natl Cancer Inst 43: 917–922, 1969.PubMedGoogle Scholar
  40. 40.
    Ankerst J, Jonsson N, Kjellen L, Norrby E, Sjogren HO. Induction of mammary fibroadenomas in rats by adenovirus type 9. Int J Cancer 13: 286–290, 1974.PubMedCrossRefGoogle Scholar
  41. 41.
    Monoz N. Effect of Herpesvirus type 2 and hormonal imbalance in uterine cervix of the mouse. Cancer Res 33: 1504–1508, 1973.Google Scholar
  42. 42.
    Wentz WB, Facog JW, Reagan JW, Heggie AD. Cervical carcinigenesis with herpes simplex virus type 2. Amer J Obs Gyn 46: 117–121, 1975.Google Scholar
  43. 43.
    Potter CW. Some aspects of the role of viruses in cancer. Postgrad Med J 55: 150–158, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Boyd AL. Characterization of single-cell clonal lines derived from HSV-2 transformed mouse cells. In- tervirol 6: 156–167, 1975.Google Scholar
  45. 45.
    Potter CW, Shortland JR, Mousway KM, Rees, RC. Comparative studies of transformed hamster cells by Herpesvirus hominis types 1 and 2. Brit J Exp Path 63: 285–298, 1982.PubMedGoogle Scholar
  46. 46.
    Todaro, GJ, Green H, Swift MR. Susceptibility of human diploid fibroblast strains to transformation by SV40. Science 153: 1252–1254, 1966.PubMedCrossRefGoogle Scholar
  47. 47.
    Butel JS, Brugge JS, Noonan CA. Transformation of primate and rodent cells by temperature-sensitive mutants of SV40. In Tumour Viruses (Cold Spring Harbour Symp.) 34: 25–36, 1974.Google Scholar
  48. 48.
    Duff R, Rapp F. Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nature 233: 48–50, 1971.CrossRefGoogle Scholar
  49. 49.
    Rapp F, Westmoreland D, Cell transformation by DNA-containing viruses. Biochimica Biophysica Acta 458: 167–211, 1976.Google Scholar
  50. 50.
    Aaronson SA. Susceptibility of human cell strains to transformation by simian virus SV40 and simian virus deoxyribonucleic acid. J Virol 6: 470–475, 1970.PubMedGoogle Scholar
  51. 51.
    Casto BC, Adenovirus transformation of hamster embryo cells. J Virol 2: 376–383, 1968.PubMedGoogle Scholar
  52. 52.
    Sambrook J. Transformation by Polyomavirus and simian virus 40. Adv Cancer Res 16: 141–180, 1972.PubMedCrossRefGoogle Scholar
  53. 53.
    Rabson AS, Kirchstein RL. Induction of malignancy in vivo in newborn hamster kidney tissue infected with simian vacuolating virus (SV40). Proc Soc Exp Biol Med 111: 323–328, 1962.PubMedGoogle Scholar
  54. 54.
    Jensen F, Koprowski H, Ponton JA. Rapid transformation of human fibroblast cultures by simian virus 40. Proc Nat Acad Sci 50: 343–348, 1963.PubMedCrossRefGoogle Scholar
  55. 55.
    Todaro GJ, Aaronson SA. Human cell strains susceptible to focus formation by human adenovirus type 12. Proc Nat Acad Sci 61: 1272–1278, 1968.PubMedCrossRefGoogle Scholar
  56. 56.
    Green M. DNA and RNA tumour viruses—molecular events of virus replication and cell transformation and role in human cancer. Adv Pathbiol 2: 10–23, 1976.Google Scholar
  57. 57.
    Galloway DA, McDougall JK. Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2. J Virol 38: 749–760, 1981.PubMedGoogle Scholar
  58. 58.
    Wyke JA. Oncogenic viruses. J Pathol 135: 39–85, 1981.PubMedCrossRefGoogle Scholar
  59. 59.
    Sambrook J, Westphal H, Srinvasan PR, Dulbecco R. The integrated state of viral DNA in SV40-trans- formed cells. Proc Nat Acad Sci 60: 1288–1295, 1968.PubMedCrossRefGoogle Scholar
  60. 60.
    Butel JS, Brugge TC, Noonan CA. Transformation of primate and rodent cells by temperature sensitive mutants of SV40: Cold Spring Harbour Symp. Quant Biol 39: 25–31, 1974.Google Scholar
  61. 61.
    Carroll RB, Smith AG. Monomer molecular weight of T antigen from simian virus 40-infected and trans¬formed cells. Proc Soc Exp Biol, Med 73: 2254–2258, 1976.Google Scholar
  62. 62.
    Rubin H, Figge J, Bladon MT, Chen LB, Ellman M, Bikel I, Farrel M, Livingston DM: Role of small t an¬tigen in the acute transforming activity of SV40. Cell 30: 469–480, 1982.PubMedCrossRefGoogle Scholar
  63. 63.
    Levine AJ. Transformation-associated tumour antigens. Adv. Cancer Res 37: 75–109, 1982.PubMedCrossRefGoogle Scholar
  64. 64.
    Hanafiisa H. Cell transformation by RNA tumour viruses. In Fraenkel-Conrat H, Wagner R (eds.), Com-prehensive virology. New York: Plenum Press, vol 10, 1977.Google Scholar
  65. 65.
    Vogt PK. The genetics of RNA tumour viruses. In Fraenkel-Conrat H, Wagner R (eds.), Comprehensive virology. New York: Plenum Press, vol 10, 1977.Google Scholar
  66. 66.
    Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci 77: 1311–1315, 1980.PubMedCrossRefGoogle Scholar
  67. 67.
    Hayman MJ. Transforming proteins of avian retroviruses. J Gen Virol 52: 1–14, 1981.PubMedCrossRefGoogle Scholar
  68. 68.
    Brugg JS, Erikson RL. Identification of a transformation specific antigen induced by avian sarcoma virus. Nature 269: 346–348, 1977.CrossRefGoogle Scholar
  69. 69.
    Duesbery PH. Transforming genes of retroviruses. Cold Spring Harbour Symp. Quant Biol 44: 13–21, 1980.Google Scholar
  70. 70.
    Shih TY, Weeks MO, Young HA, Scolnick EM. Identification of a sarcoma virus coded phosphoprotein in the non-producer cells transformed by Kirsten or Harvey murine sarcoma viruses. Virology 96: 64–79, 1979.PubMedCrossRefGoogle Scholar
  71. 71.
    Graf T, Beug H. Avian leukaemia viruses. Interaction with their target cells, in vivo and in vitro. Biochim Biophys Acta 516: 269–299, 1978.Google Scholar
  72. 72.
    De Larco JE, Tadaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Nat Acad Sci 75: 4001–4005, 1978.PubMedCrossRefGoogle Scholar
  73. 73.
    Langan T. Malignant transformation and protein phosphorylation. Nature 286: 329–330, 1980.PubMedCrossRefGoogle Scholar
  74. 74.
    Weil R. Viral “tumour antigen”: A novel type of mammalian regulator protein. Biochim Biophys Acta 516: 310–388, 1978.Google Scholar
  75. 75.
    Hayward WS, Weel BG, Astrin SM. Avian lymphoid leukosis is correlated with the appearance of discrete new RNAs containing viraland cellular genetic information: In Neth R, Gallo R (eds.), Modern trends in human leukaemia. Munich: Bergerman Verlag, 1981.Google Scholar
  76. 76.
    Stephenson JR. Type C virus structural and transformation-specific proteins. In Stephenson JR (ed.), Molecular biology of RNA tumour viruses. New York: Academic Press, 1980.Google Scholar
  77. 77.
    Old LJ, Stockert E. Immunogenetics of cell surface antigens of mouse leukaemia. Anns Rev Genet 11: 127–160, 1977.CrossRefGoogle Scholar
  78. 78.
    Coggin JH, Ambrose KR. Embryonic and foetal determinants on virally and chemically induced tumours. Methods Cancer Res 18: 371–389, 1979.Google Scholar
  79. 79.
    Black PH, Rowe WP, Turner HC, Huebner RJ. A specific complement-fixing antigen present in SV40 tumour and transformed cells. Proc Nat Acad Sci 50: 1148–1156, 1963.PubMedCrossRefGoogle Scholar
  80. 80.
    Potter CW, McLaughlin BC, Oxford JS. Simian virus 40-induced T and tumour antigen. J Virol 4: 574– 579, 1969.Google Scholar
  81. 81.
    Ahmed-Zadeh C, Allet B, Greenblatt J, Weil R. Two forms of the simian virus-40-specific T-antigen in abortive and lytic infection. Proc Nat Acad Sci 73: 1097–1101, 1976.CrossRefGoogle Scholar
  82. 82.
    Pope JH, Rowe WP. Detection of specific antigen in SV40-transformed cells by immunofluorescence. J Exp Med 120: 121–128, 1964.PubMedCrossRefGoogle Scholar
  83. 83.
    Schild GC, Oxford JS, Potter CW. Changes accompanying long-term tissue culture of an adenovirus type 12 tumour cell line. Brit J Cancer 22: 798–807, 1968.PubMedCrossRefGoogle Scholar
  84. 84.
    Anderson JL, Martin RG, Chang C, Mora PT, Livingstone D. Nuclear preparations of SV40-transformed cells contain tumour specific transplantation antigen activity. Virology 76: 420–425, 1977.PubMedCrossRefGoogle Scholar
  85. 85.
    Girardi AJ. Prevention of SV40 virus oncogenesis in hamsters. I. Tumour resistance induced by human cells tranformed by SV40. Proc Nat Acad Sci 54: 445–451, 1965.PubMedCrossRefGoogle Scholar
  86. 86.
    Potter CW, Hoskins JM, Oxford JS. Immunological relationship of some oncogenic DNA viruses. I. Transplantation immunity studies. Arch Ges Virusforsch 27: 73–86, 1969.PubMedCrossRefGoogle Scholar
  87. 87.
    Zarling JM, Tevethia SS. Transplantation immunity to simian virus-40 transformed cells in tumour bearing mice. I. Development of cellular immunity to simian virus 40 tumour specific transplantation antigens dur¬ing tumourigenesis by transformed cells. J Natl Cancer Inst 50: 137–147, 1980.Google Scholar
  88. 88.
    Tevethia SS, Greenfield RS, Flyer DC, Tevethia MJ. SV40 transplantation antigen: Relationship to SV40- specific proteins. Cold Spring Harbour Symp. Quant Biol 44 (Pt. 1): 235–242, 1980.Google Scholar
  89. 89.
    Smith RW, Morganroth J, Mora PT. SV40 virus-induced tumour specific transplantation antigen in cul¬tured mouse cells. Nature 227: 141–145, 1971.CrossRefGoogle Scholar
  90. 90.
    Rogers MJ, Low LW. Immunogenic properties of a soluble tumour rejection antigen (TSTA) from a simian virus 40-induced sarcoma. Int J Cancer 23: 89–96, 1979.PubMedCrossRefGoogle Scholar
  91. 91.
    Lewis AM Jr, Rowe WP. Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VIII. Association of simian virus 40 transplantation antigen with a specific region of the early viral genome. J Virol 12, 836–840, 1973.PubMedGoogle Scholar
  92. 92.
    Girardi AJ, Defendi V. Induction of SV40 transplantation antigen (TrAg) during the lytic cycle J Virol 42, 688–698, 1970.Google Scholar
  93. 93.
    Tegtmeyer P, Schwatz M., Collins JK, Rundell K. Regulation of tumour antigen synthesis by simian virus 40 gene. J Virol 16: 168–178, 1975.PubMedGoogle Scholar
  94. 94.
    Crawford LV, Pim DC, Lane DP. An immunochemical investigation of SV40 T antigens. II. Quantitation of antigen and antibody activities. Virology 100: 314–325, 1980.PubMedCrossRefGoogle Scholar
  95. 95.
    Greenfield RS, Flyer DC, Tevethia SS. Demonstration of unique and common antigenic sites located on the SV40 large T and small t antigens. Virology 104, 312–322, 1980.PubMedCrossRefGoogle Scholar
  96. 96.
    Chang C, Martin RG, Livingston DM, Luborsky SW, Hu C, Mora PT. Relationship between T-antigen and tumour specific transplantation antigen in simian virus 40 transformed cells. J Virol 29: 69–75, 1979.PubMedGoogle Scholar
  97. 97.
    Morrow JF, Berg P, Kelly TJ Jr., Lewis AM Jr. Mapping of simian virus 40 early functions on the viral chromosome. J Virol 12, 653–658, 1973.PubMedGoogle Scholar
  98. 98.
    Jay G, Jay FT, Chang C, Friedman RM, Levrin AS. Tumour specific transplantation antigen: Use of the Ad2+ NDj hybrid virus to identify the proteins responsible for simian virus 40 tumour rejection and its genetic origin. Proc Natl Acad Sci 75, 3055–3059, 1978.PubMedCrossRefGoogle Scholar
  99. 99.
    Jay G, Jay FT, Chang C, Levine AS, Friedman RM. Induction of simian virus 40-specific tumour rejection by the Ad2+ ND2 hybrid virus. J Gen Virol 44: 287–296, 1979.PubMedCrossRefGoogle Scholar
  100. 100.
    Tevethia SS, Flyer DC, Trian R. Biology of simian virus 40 (SV40) transplantation antigen (TrAG). Virology 107: 13–23, 1980.PubMedCrossRefGoogle Scholar
  101. 101.
    Law LW, Rogers MJ, Apella E. Tumour antigens in neoplasms induced by chemical carcinogens and by DNA and RNA-containing viruses: Properties of the solubilised antigens. Adv Cancer Res 32: 201–215, 1980.Google Scholar
  102. 102.
    Duff R, Doller E, Rapp F. Immunologic manipulation of metastases due to Herpesvirus transformed cells. Science 180: 79–81, 1973.PubMedCrossRefGoogle Scholar
  103. 103.
    Mousawy KM, Rees RC, Potter CW. Immunogenic properties of hamster tumours of Herpesvirus hominis aetiology. Cancer Immunol Immunother 8: 119–126, 1980.CrossRefGoogle Scholar
  104. 104.
    Baver H. Virion and tumour antigens of C-type RNA tumour viruses. Adv Cancer Res 20: 275–341, 1975.Google Scholar
  105. 105.
    Old LJ, Boyse EA, Stockert E. The G(Gross) leukaemia antigen. Cancer Res 25: 813–819, 1965.PubMedGoogle Scholar
  106. 106.
    Geering G, Old LJ, Boyse EA. Antigens of leukaemia induced by naturally occurring murine leukaemia virus: Their relation to the antigen of Gross virus and other murine leukaemia viruses. J Exp Med 124: 753–772, 1966.PubMedCrossRefGoogle Scholar
  107. 107.
    Grant CK, De Noronha F, Tusch C, Michalek MT, McLane MF. Protection of cats against progressive fibrosarcomas and persistent leukaemia virus infection by vaccination with feline leukaemia cells. J Natl Cancer Inst 65: 1285–1291, 1980.PubMedGoogle Scholar
  108. 108.
    Ledbetter J, Nowinski RC, Emery S. Viral proteins on the surface of murine leukaemia cells. J Virol 22: 65–73, 1977.PubMedGoogle Scholar
  109. 109.
    Hunsmann G, Moennig V, Schafer W. Properties of mouse leukaemia viruses. IX. Active and passive immunization of mice against friend leukaemia and isolated viral GP71 glycoprotein and to corresponding an-tiserum. Virology 66: 327–329, 1975.PubMedCrossRefGoogle Scholar
  110. 110.
    De Noronha F, Baggs, R, Schafer W, Bolognesi DP. Prevention of oncornavirus-induced sarcomas in cats by treatment with antiviral antibodies. Nature 267: 54–56, 1977.PubMedCrossRefGoogle Scholar
  111. 111.
    Rogers MJ, Law LW, Appella E. Solubilized TSTA and the major viral structural proteins gp70 and p30 in the immune response to murine leukaemia induced by Friend and Rauscher virus. Int J Cancer 20: 303–308, 1977.PubMedCrossRefGoogle Scholar
  112. 112.
    Rees RC, Potter CW, Shelton J. The specificity of cellular immune reactions to three DNA virus-induced tumours as measured by the macrophage migration inhibition test. Europ J Cancer 11: 79–86, 1975.CrossRefGoogle Scholar
  113. 113.
    Sjogren HO, Minowada J, Ankerst J. Specific transplantation antigens of mouse sarcomas induced by adenovirus type 12. J Exp Med 125: 689–701, 1967.PubMedCrossRefGoogle Scholar
  114. 114.
    Rees RC, Potter CW. In vivo studies of cell-mediated and humoral immune responses to adenovirus 12-induced tumour cells. Ach Ges Virusforsch 41: 116–126, 1973.Google Scholar
  115. 115.
    Blasecki JW, Tevethia SS. Restoration of specific immunity against SV40 tumour-specific transplantation antigens to lymphoid cells from tumour-bearing mice. Int J Cancer 16: 275–283, 1975.PubMedCrossRefGoogle Scholar
  116. 116.
    Gooding LR. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J Immunol 118: 920–927, 1977.PubMedGoogle Scholar
  117. 117.
    Gooding LR. Specificities of killing by T-lymphocytes generated against syngeneic SV40 transformants: Studies employing recombinants with the H2 complex. J Immunol 122: 1002–1008, 1979.PubMedGoogle Scholar
  118. 118.
    Gooding LR. T-lymphocyte effectors generated against SV40 transformed cells. J Immunol 121: 2328–2336, 1979.Google Scholar
  119. 119.
    Blasecki JW. Functional analysis of lymphoid cell subpopulations involved in rejection of tumours induced by simian virus 40. In Streilen JW, Hart DA, Stein-Streilen J, Duncan WR, Billingham RE (eds.), Hamster immune responses in infections and oncologic diseases. New York: Plenum Press, 1981, pp. 123–134.Google Scholar
  120. 120.
    Allison AC. Immune responses to polyoma virus-induced tumours. In Klein G. (ed.), Viral oncology. New York: Raven Press, 1980, pp. 481–488.Google Scholar
  121. 121.
    Schroder JW, Henning R, Molner RJ, Edelman GM. The recognition of H2 and viral antigens by cytotoxic T-cells. Cold Spring Harbour, Quant Biol 41: 547–558, 1976.Google Scholar
  122. 122.
    Doherty PC, Gotle D, Trinchieri G, Zinkernagel RM. Models for recognition of virally modified cells by immune thymus-derived lymphocytes. Immunogenetics 3: 517–524, 1976.CrossRefGoogle Scholar
  123. 123.
    Gooding LR, Edwards CB. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T-lymphocytes. J Immunol 124: 1258–1262, 1980.PubMedGoogle Scholar
  124. 124.
    Campbell AE, Foley FM, Tevethia SS. Demonstration of multiple antigenic sites of the SV40 transplanta¬tion rejection antigen by using cytotoxic T-lymphocyte clones. J Immunol 130: 490–492, 1983.PubMedGoogle Scholar
  125. 125.
    Mitulska ZB, Smith C, Alexander P. Evidence for an immunological reaction of the host directed against its own actively growing primary tumour. J Natl Cancer Inst 36: 29–35, 1966.Google Scholar
  126. 126.
    Barski G. Youn JK. Evolution of cell-mediated immunity in mice bearing an antigenic tumour. Influence of tumour growth and surgical removal. J Natl Cancer Inst 43: 111–112, 1969.PubMedGoogle Scholar
  127. 127.
    Herberman RB, Aoki T, Nunn ME, Lavrin DH, Soares N, Gazdar A, Holden H, Chang KSS. Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst 53: 1103– 1111, 1974.Google Scholar
  128. 128.
    Blesecki JW, Tevethia SS. In vitro studies on the cellular immune response of tumour-bearing mice to SV40-transformed cells. J Immunol 114, 244–249, 1975.Google Scholar
  129. 129.
    Zarling JM, Tevethia SS. Transplantation immunity to Simian virus-40-transformed cells in tumour-bearing mice. I. Development of cellular immunity to Simian virus 40 tumour-specific transplantation antigen dur¬ing tumourigenesis by transplanted cells. J Natl Cancer Inst 50: 137–147, 1973.PubMedGoogle Scholar
  130. 130.
    Rees RC, Potter CW. Immune response to adenovirus 12-induced tumour antigens, as measured in vitro by the macrophage migration inhibition test. Europ J Cancer 9: 497–502, 1973.CrossRefGoogle Scholar
  131. 131.
    Blesecki JW, Tevethia SS. In vitro assay of cellular immunity to tumour-specific antigen(s) of virus-induced tumours by macrophage migration inhibition. J Immunol 110: 590–594, 1973.Google Scholar
  132. 132.
    Mortensen RF, Ceglowski WS, Friedman H. In vitro assessment of cellular immunity to Rauscher leu¬kaemia virus. J Immunol 111: 657–660, 1973.Google Scholar
  133. 133.
    Datta SK, McCormick KJ, Trentin JJ. Induction of tumour-specific cell-mediated immunity by a non¬infectious type-C virus. Infect Immun 33: 126–129, 1981.PubMedGoogle Scholar
  134. 134.
    Koppi TA, Halliday WJ. Regulation of cell-mediated immunologic reactivity to Moloney murine sarcoma virus-induced tumours. I. Cell and serum activity detected by leukocyte adherence inhibiton. J Natl Cancer Inst 66: 1089–1096, 1981.PubMedGoogle Scholar
  135. 135.
    Koppi TA, Halliday WJ, McKenzie IF. Regulation of cell-mediated immunologic reactivity to Moloney murine sarcoma virus-induced tumours. II. Nature of blocking and unblocking factors in serum. J Natl Cancer Inst 66: 1097–1102, 1981.PubMedGoogle Scholar
  136. 136.
    Nahmias AJ, Sawanabori S. The genital herpes-cervical cancer hypothesis—10 years later. Prog Exp Tumour Res 21: 117–125, 1978.Google Scholar
  137. 137.
    Shortland J, Mousway KM, Rees RC, Potter CW. Tumourigenicity of Herpesvirus hominis type 2 trans¬formed cells (line 333-8-9) in adult hamsters. J Path 129: 169–178, 1979.PubMedCrossRefGoogle Scholar
  138. 138.
    Mousway KM, Rees RC, Potter CW, Shortland JR. Immune response of hamsters to transplanted herpes¬virus induced tumours. In Letnansky (ed.), Biology of the cancer cell. Kugler Medical Publ, 1980, pp. 127–132.Google Scholar
  139. 139.
    Walker JR, Rees RC, Teale DM, Potter CW. Properties of a Herpesvirus-transformed hamster cell line. I. Growth and culture characteristics of sublines of high and low metastatic potential. Europ J Cancer Clin Oncol 18: 1017–1026, 1982.PubMedCrossRefGoogle Scholar
  140. 140.
    Gorlik E, Fogel M, Baetselier P, Katzav S, Feldman M, Segal S. Immunobiological diversity of metastatic cells. In Liotta LA, Hart IT (eds.), Immune invasion and metastases. The Hague: Martinus Nijhoff, 1982, pp. 133–146.Google Scholar
  141. 141.
    Levy JP, Leclerc JC. The murine sarcoma virus induced tumour: Exception or general model in tumour immunology. Adv Cancer Res 24: 1–66, 1977.PubMedCrossRefGoogle Scholar
  142. 142.
    Gomard E, Duprez V, Reme T, Colombani MJ, Levy JP. Exclusive involvement of H-2db or H-2Kd products in the interaction between T-killer lymphocyte and syngeneic H-2b and H-2d viral lymphomas. J Exp Med 146: 909–922, 1977.PubMedCrossRefGoogle Scholar
  143. 143.
    Gomard E, Levy JP, Plata F, Henin Y, Duprez V, Bismuth A, Reme T. Studies on the nature of the cell surface antigen reacting with cytolytic T-lymphocytes in murine oncornavirus-induced tumours. Europ J Immunol 8: 228–236, 1978.CrossRefGoogle Scholar
  144. 144.
    Enjuanes L, Lee I. Antigenic specificities of the cellular immune response of C57B1/6 mice to the Moloney leukaemia/sarcoma virus complex. J Immunol 122: 665–674, 1979.PubMedGoogle Scholar
  145. 145.
    Zarling DA, Keshet I, Watson A, Bach FH. Association of mouse major histocompatibility and Rauscher murine leukaemia virus envelope glycoprotein antigens on leukaemia cells and their recognition by syngeneic virus-immune-cytotoxic T-lymphocytes. Scand J Immunol 8: 497–508, 1978.PubMedCrossRefGoogle Scholar
  146. 146.
    Watson A, Bach FH. The role of gp70 in the target antigen recognised by murine leukaemia virus immune cytotoxic T-lymphocytes. Int J Cancer 26: 483–494, 1980.PubMedCrossRefGoogle Scholar
  147. 147.
    Collins JJ, Sanfilippo F, Tsong-Chou L, Ishizaki R, Metzgar RS. Immunotherapy of murine leukaemia. I. Protection against Friend leukaemia virus-induced disease by passive serum therapy. Int J Cancer 21: 51–61, 1978.PubMedCrossRefGoogle Scholar
  148. 148.
    Charman HP, Kim N, Gilden RV, Hardy WD Jr., Essex M. Humoral immune response of cats to feline leukaemia virus: Comparison of responses to the major structural protein p30 and to a virus-specific cell membrane antigen (FOCMA). J Natl Cancer Inst 57: 1095–1099, 1976.Google Scholar
  149. 149.
    Grant CK, Pickard DK, Ramaika C, Madewell BR, Essex M. Complement and tumour antibody levels in cats, and changes associated with natural feline leukaemia virus infection and malignant disease. Cancer Res 39: 75–81, 1979.PubMedGoogle Scholar
  150. 150.
    Grant CK, Essex M, Gardner MB, Hardy WD Jr. Natural feline leukaemia virus infection and the immune response of cats of different ages. Cancer Res 40: 823–829, 1980.PubMedGoogle Scholar
  151. 151.
    Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res 27: 305–377, 1978.PubMedCrossRefGoogle Scholar
  152. 152.
    Rees RC, Underwood JCE. Tumour immunology. In Hancock BW (ed.), Assessment of tumour response. The Hague/Boston/London: Martinus Nijhoff, 1982, pp. 181–210.Google Scholar
  153. 153.
    Herberman RB. Natural killer cells and other natural effector cells. New York: Academic Press, 1982.Google Scholar
  154. 154.
    Hanna N. The role of natural killer (NK) cells in the control of tumour metastasis. In Liotta LA, Hart IR (eds.), Tumour Invasion and Metastases. The Hague: Martinus Nijhoff, 1982, pp. 29–41.Google Scholar
  155. 155.
    Fernandez-Cruz E, Halliburton B, Feldman JD. In vivo elimination by specific effector cells of an estab¬lished syngeneic rat Moloney virus-induced sarcoma. J Immunol 123: 1772–1777, 1979.Google Scholar
  156. 156.
    Platta F, MacDonald, HR, Sordat B. Studies on the distribution and origin of cytolytic T-lymphocytes present in mice bearing Moloney murine sarcoma virus (MSV)-induced tumours. Bibl Haematol 43: 274–277, 1976.Google Scholar
  157. 157.
    Becker S, Klein E. Defective cytotoxic T-cell generation in Moloney murine sarcoma virus-infected A/Sn mice. J Natl Cancer Inst 65: 811–816, 1980.PubMedGoogle Scholar
  158. 158.
    Stutman O. Natural and induced immunity to mouse mammary tumours and the mammary tumour virus (MuMTV). Springer Semin Immunopathoi 4: 333–372, 1982.CrossRefGoogle Scholar
  159. 159.
    Teale DM, Rees RC, Clark A, Walker JR, Potter CW. Reduced susceptibility of NK cell lysis of hamster tumours exhibiting high levels of spontaneous metastasis. Cancer Letters (in press).Google Scholar
  160. 160.
    Epstein MA, Achong BG. The Epstein-Barr virus. Berlin: Springer Verlag, 1979.Google Scholar
  161. 161.
    Lindahl T, Adams A, Bjursell G, Bornkamn GW, Kaschka-Dierick C, Jehn V. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol 102: 511–530, 1976.PubMedCrossRefGoogle Scholar
  162. 162.
    Lindahl T, Klein G, Reedman BM, Johannson B, Singh S. Relationship between Epstein-Barr (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma and other lymphoproliferative malignancies. Int J Cancer 13: 764–772, 1974.PubMedCrossRefGoogle Scholar
  163. 163.
    Josey WE, Nahmias AJ, Naib ZM. Viruses and cancer of the lower genital tract. Cancer 38: 526–533, 1976.PubMedCrossRefGoogle Scholar
  164. 164.
    Melnick JL, Adam E. Epidemiological approaches to determining whether Herpesvirus is the etiological agent of cervical cancer. Prog Exp Tumour Res 21: 49–69, 1978.Google Scholar
  165. 165.
    Nahmias AJ, Naib ZM, Josey W. Epidemiological studies relating genital herpes to cervical cancer. Cancer Res 3: 1111–1117, 1974.Google Scholar
  166. 166.
    Rawls WE, Adam E. Herpes simplex viruses and human malignancies. In Hiatt, HH, Watson JD, Winston JA (eds.), Origins of Human Cancer. Cold Spring Harbour 4: 1133–1155, 1977.Google Scholar
  167. 167.
    Melnick JL, Adam E, Lewis R, Kaufman RH. Cervical cancer cell lines containing Herpesvirus markers. Intervirology 12: 111–114, 1979.PubMedCrossRefGoogle Scholar
  168. 168.
    Aurelian L. Virions and antigens of Herpesvirus type 2 in cervical carcinoma. Cancer Res 33: 1539–1547, 1973.PubMedGoogle Scholar
  169. 169.
    Frankel N. Roizman B, Cassai E, Nahmias A. A DNA fragment of herpes simplex 2 and its transcription in human cervical cancer tissue. Proc Natl Acad Sci 69: 3784–3789, 1972.CrossRefGoogle Scholar
  170. 170.
    Jones JW, Fenoglio CM, Shevchok-Chaban M, Maitland NJ, McDougallJK. Detection of herpes simplex virus type 2 mRNA in human cervical biopsies by in situ cytological hybridization. IARC Sci Publ 24: 917–925, 1979.Google Scholar
  171. 171.
    Kessler I. Human cervical cancer as a venereal disease. Cancer Res 36: 783–791, 1976.PubMedGoogle Scholar
  172. 172.
    Ishiguro T, Ozarki Y. Antibodies to herpes simplex virus in cervical cancer. Adv Obstet Gynecol (Jpn) 30: 9–13, 1978.Google Scholar
  173. 173.
    Ory H. Conger B, Richart R, Barron B. Relation of type 2 Herpesvirus antibodies to cervical neoplasia: Barbados, West Indies, 1971. Obstet Gynecol 43: 901–904, 1974.Google Scholar
  174. 174.
    Vestergaard BF, Hornsleth A, Pedersen SN. Occurrence of herpes- and adenovirus antibodies in patients with carcinoma of the cervix uteri. Cancer 30: 68–74, 1972.PubMedCrossRefGoogle Scholar
  175. 175.
    Reid R, Stanhope CR, Herschman BR, Booth E, Phibbs GD, Smith JP. Genital warts and cervical cancer. Cancer 50: 377–387, 1982.PubMedCrossRefGoogle Scholar
  176. 176.
    Green M, Brackman KH, Sanders PR, Loewenstein PM, Freel JH, Eisinger M, Switlyx SA. Isolation of a human Papillomavirus from a patient with epidermodysplasia verruciformis. Proc Natl Acad Sci 79: 4437– 4441, 1982.Google Scholar
  177. 177.
    Gissmann L, de Villiers EM, Zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumours for human Papillomavirus type 6 DNA. Int J Cancer 29: 143–146, 1982.Google Scholar
  178. 178.
    Zur Hausen H. Human Papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78: 1–30, 1977.PubMedGoogle Scholar
  179. 179.
    Orth G, Faure M, Jablonska S, Brylak K, Croissant O. Viral sequences related to a human skin Papilloma¬virus in genital warts. Nature 275: 334–336, 1978.PubMedCrossRefGoogle Scholar
  180. 180.
    Zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 36: 794, 1976.PubMedGoogle Scholar
  181. 181.
    Friedman-Kien AE. Disseminated Kaposi’s sarcoma syndrome in young homosexual men. J Amer Acad Dermatol 5: 468–471, 1981.CrossRefGoogle Scholar
  182. 182.
    Hymes KB, Greene JB, Marcos A, William DC, Cheung T, Prose NS, Ballard H, Laubenstein LJ. Kaposi’s sarcoma in homosexual men. Lancet 2: 598–600, 1981.PubMedCrossRefGoogle Scholar
  183. 183.
    Giraldo G, Beth E, Henle W, Henle G, Mike V, Safai B, Huraux JM, McHardy J, de The G. Antibody pat¬terns to Herpesviruses in Kaposi’s sarcoma. Int J Cancer 22: 126–131, 1978.Google Scholar
  184. 184.
    Tong MG, Sun SC, Schaeffer BT. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med 75: 687–691, 1971.PubMedGoogle Scholar
  185. 185.
    Beasley RP, Hwana LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2: 1129–1133, 1981.Google Scholar
  186. 186.
    Edman JC, Gray P, Valenzuela P, Rail LB, Rutter WJ. Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 286: 535–538, 1980.PubMedCrossRefGoogle Scholar
  187. 187.
    Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA se¬quences in cellular DNA of human hepatocellular carcinoma. Nature 286: 533–535, 1980.PubMedCrossRefGoogle Scholar
  188. 188.
    Johnson PJ, Williams R. Of woodchucks and man: The continuing story of hepatitis B and hepatocellular carcinomas. Brit Med J 284: 1586–1588, 1982.Google Scholar
  189. 189.
    Howley PM. DNA sequences of human Papovavirus BK. Nature 284: 124–125, 1980.PubMedCrossRefGoogle Scholar
  190. 190.
    Schernecks S, Rudolph M, Geissler E. Isolation of an SV40-like Papovavirus from a human glioblastoma. Int J Cancer 24: 523–531, 1979.CrossRefGoogle Scholar
  191. 191.
    Brovet JC, Flandrin G, Seligmann M. Indication of the thymus derived nature of the proliferating cells in six patients with Sezary’s syndrome. N Eng J Med 289: 341–344, 1973.CrossRefGoogle Scholar
  192. 192.
    Thivolet J, Fulton R, Souteyrand P, Gaucherand M, Claudy A. Sezary syndrome: Relative increase in T helper lymphocytes demonstrated by monoclonal antibodies. Acta Derm Venereal 62: 337–340, 1982.Google Scholar
  193. 193.
    Edelson RL. Cutaneous T cell lymphoma: Mycosis fungoides, Sezary syndrome and other variants. J Amer Acad Dermatol 2: 89–106, 1980.CrossRefGoogle Scholar
  194. 194.
    Neth R, Gallo RC, Graff K, Mannweiler K. Regulation of human T-cell proliferation: T-cell growth factor and isolation of a new class of type-C retroviruses. In Winkler K (ed.), Modern trends in human leukaemia 4: 502–514, 1981.Google Scholar
  195. 195.
    Blattner WA, Kalyanaraman VS, Robert-Guroff M, Lister A, Galton DAG, Sarin PS, Crawford MH, Catousky D, Greaves M, Gallo RC. The human type-C retrovirus HTLV in blacks from the Caribbean region and relationship to adult T-cell leukaemia/lymphoma. Int J Cancer 30: 257–264, 1982.PubMedCrossRefGoogle Scholar
  196. 196.
    Bishop JM. Retrovirus and cancer genes. Adv Cancer Res 37: 1–32, 1982.PubMedCrossRefGoogle Scholar
  197. 197.
    Syrjanen KJ. Demonstration of human Papillomavirus antigen in the condylomatous lesions of the uterine cervix. Lancet 2: 125–127, 1982.Google Scholar
  198. 198.
    Maupas PH, Goudeau A, Coursaget P, Chiron JP, Drucker J, Barin F, Perrin J, Denis F, Diopmar I. Hepatitis B virus infection and primary hepatocarcinoma. In Essex M, Tadoro G, Zur Hausen H (eds.), Viruses and naturally occurring cancer. Cold Spring Harbour Conference on Cell Proliferation 7: 481–506, 1980.Google Scholar
  199. 199.
    Normura A, Grant N, Stemmerman N, Wasnick RD. Presence of hepatitis B surface antigen before pri¬mary hepatocellular carcinoma. JAMA 247: 2247–2249, 1982.CrossRefGoogle Scholar
  200. 200.
    Melnick JL, Adam E, Lewis R, Kaufman RH. Cervical cancer cell lines containing Herpesvirus markers. Intervirol 12: 111–114, 1979.CrossRefGoogle Scholar
  201. 201.
    Dreesman GR, Burch J, Ada E, Kaufman RH, Melnick JL, Powell KL, Purifoy DJ. Expression of Herpes- virus-induced antigens in human cervical cancer. Nature 283: 591–593, 1980.PubMedCrossRefGoogle Scholar
  202. 202.
    Smith CC, Aurelian L, Gupta PK, Frost JK, Rosenhein NB, Klacsmann K, Geddes S. An evaluation of herpes simplex virus antigenic markers in the study of established and developing cervical neoplasia. Anal- Quant Cytol 2: 131–143, 1980.PubMedGoogle Scholar
  203. 203.
    Hollinshead AC, Tarro C. Soluble membrane antigens of LIP and cervical carcinomas. Science 179: 698–700, 1973.PubMedCrossRefGoogle Scholar
  204. 204.
    Gall SA, Haines HG. Cervical carcinoma antigen and the relationship to HSV-2. Gynecol Oncol 2: 451–459, 1974.CrossRefGoogle Scholar
  205. 205.
    Notter MF, Docherty JJ, Mortel R, Hollinshead AC. Detection of herpes simplex vims tumour-associated antigen in uterine cervical cancer tissue. Gynecol Oncol 6: 574–581, 1978.PubMedCrossRefGoogle Scholar
  206. 206.
    Weiner LP, Herndon RM, Johnson RT. Viral infections and demyelinating diseases. N Eng J Med 288: 1103–1110, 1973.CrossRefGoogle Scholar
  207. 207.
    Weiner LP, Narayan O. Virological studies in progressive multifocal leukoencephalopathy. Prog Med Virol 18: 229–240, 1974.PubMedGoogle Scholar
  208. 208.
    Weiss AF, Portmann R, Fischer H, Simon J, Zang KD. Simian virus 40-related antigens in three human meningiomas with defined chromosome breaks. Proc Natl Acad Sci 72: 609–613, 1975.PubMedCrossRefGoogle Scholar
  209. 209.
    Pope JH, Home MK, Wetters EJ. Significance of a complement-fixing antigen associated with herpes-like virus and detected in the Raji cell line. Nature 222: 186–187, 1969.PubMedCrossRefGoogle Scholar
  210. 210.
    Reedman BM, Klein G. Cellular localisation of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer cells and non-producer lymphoblastoid cell lines. Int J Cancer 11: 499–520, 1973.PubMedCrossRefGoogle Scholar
  211. 211.
    Zur Hausen H. Biochemical approaches to detection of Epstein-Barr virus in human tumours. Cancer Res 36: 678–681, 1976.PubMedGoogle Scholar
  212. 212.
    Henle W, Henle G, Zagac B, Pearson G, Waubke R, Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 169: 188–189, 1970.PubMedCrossRefGoogle Scholar
  213. 213.
    Svedmyr E, Jondal M. Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci 72: 1622–1628, 1975.PubMedCrossRefGoogle Scholar
  214. 214.
    Levine AJ. Transformation-associated tumour antigens. Adv Cancer Res 37: 75–109, 1982.PubMedCrossRefGoogle Scholar
  215. 215.
    Crawford LV, Pim DC, Gurney EG. Goodfellow P, Taylor-Papadimitrou A. Detection of a common feature in several human tumour lines—A 53,000-dalton protein. Proc Natl Acad Sci 787: 41–45, 1981.CrossRefGoogle Scholar
  216. 216.
    Catovsky D, Greaves MF, Rose M, Galton DAG, Goolden AWG, McCluskey DR, White JM, Lampert I, Bourikas G, Ireland R, Bridges JM, Blather WAC, Gallo RC. Adult T-cell lymphoma leukaemia in blacks from the West Indies. Lancet 1: 639–643, 1982.PubMedCrossRefGoogle Scholar
  217. 217.
    Tomana M, Kajdos AH, Niedeimeier W, Durkin WJ, Mestecky J. Antibodies to mouse mammary tumour virus-related antigen in sera of patients with breast carcinoma. Cancer 47: 2696–2703, 1981.PubMedCrossRefGoogle Scholar
  218. 218.
    Zachrau RE, Black MM, Dion AS, Shore B, Isac M, Andrade AM, Williams CJ. Prognostically significant protein components in human breast cancer tissue. Cancer Res 36: 3143–3146, 1976.PubMedGoogle Scholar
  219. 219.
    Mesa-Tejada R, Oster MW, Fenoglio CM, Majidson J, Spiegelman S. Diagnosis of primary breast carcinoma through immunochemical detection of antigen related to mouse mammary tumour virus metastatic lesions: A report of two cases. Cancer 15: 261–268, 1982.Google Scholar
  220. 220.
    Black MM, Zachrau RE, Dion AS, Shire B, Fine DL, Leis HP Jr, Williams CJ. Cellular hypersensitivity to gp55 of Rlll-murine tumour virus and gp55-like protein of human breast cancers. Cancer Res 36: 4137– 4142, 1976.Google Scholar
  221. 221.
    Cannon GB, Barsky SH, Alford TC, Jerome LF, Tinley V, McCoy JL, Dean JH. Cell-mediated immunity to mouse mammary tumour virus antigens by patients with hyperplastic benign breast disease. J Natl Cancer Inst 68: 935–943, 1982.PubMedGoogle Scholar
  222. 222.
    Holder WD Jr, Wells SA Jr. Antibody reacting with the murine mammary tumour virus in the serum of patients with breast carcinoma: A possible serological detection method for breast carcinoma. Cancer Res 43: 239–244, 1983.PubMedGoogle Scholar
  223. 223.
    Hewetson JF, Levine PH, Neubauer RH. Rubin H. Discordant Epstein-Barr virus molecular antigen (EBNA) antibody patterns in nasopharyngeal carcinoma. Int J Cancer: 581–585, 1982.Google Scholar
  224. 224.
    Falaky IHE, Vestergaard BF. IgG-, IgA- and IgM-antibodies to herpes simplex virus type 2 in sera from patients with cancer of the uterine cervix. Europ J Cancer 13: 247–251, 1977.CrossRefGoogle Scholar
  225. 225.
    Pasca AS, Kummerlauder L, Pejtsik B, Pali K. Herpesvirus antibodies and antigens in patients with cervical anaplasia and in controls. J Natl Cancer Inst 55: 775–781, 1975.Google Scholar
  226. 226.
    Cristenson B. Antibody-dependent cell-mediated cytotoxicity to HSV transformed cells in the course of cervical carcinoma. Am J Epidemiol 115: 556–568, 1982.PubMedGoogle Scholar
  227. 227.
    Arsenakis M, May JT, Cauchi MN. Antibody to AG-4 and survival of carcinoma of the cervix patients. Lancet 2: 437, 1981.CrossRefGoogle Scholar
  228. 228.
    Heise ER, Kucera LS, Raben M, Homesley H. Serological response patterns to herpes virus type 2 early and late antigens in cervical carcinoma patients. Cancer Res 39: 4022–4026, 1979.PubMedGoogle Scholar
  229. 229.
    Christenson B, Espmark A. Long-term follow-up studies on herpes simplex antibodies in the course of cervical cancer. II. Antibodies to surface antigen of herpes simplex virus infected cells. Int J Cancer 17: 318–325, 1976.PubMedCrossRefGoogle Scholar
  230. 230.
    Christenson B. Antibody-dependent cell-mediated cytotoxicity to herpes simplex virus type 2 infected target cells, in the course of cervical carcinoma. Amer J Epidem 108: 126–135, 1978.Google Scholar
  231. 231.
    Notter MFD, Docherty JJ. Reaction of antigens isolated from herpes simplex virus-transformed cells of squamous cell carcinoma patients. Cancer Res 36: 4394–4401, 1976.PubMedGoogle Scholar
  232. 232.
    Brown P, Tsai T, Gajdusek DC. Seroepidemiology of human Papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Amer J Epidem 102: 331 - 340, 1975.Google Scholar
  233. 233.
    Gardner SD. Prevalence in England of antibody to human Polyomavirus (BK). Brit Med J 1: 77–78, 1973.PubMedCrossRefGoogle Scholar
  234. 234.
    Padgett BL, Walker DL. New human Papovaviruses. Progr Med Virol 22: 1–35, 1976.Google Scholar
  235. 235.
    Penn I. Tumours arising in organ transplant recipients. Adv Cancer Res 28: 31–61, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston/Dordrecht/Lancaster 1985

Authors and Affiliations

  • C. W. Potter
  • R. C. Rees

There are no affiliations available

Personalised recommendations